Polycystic Ovarian Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major polycystic ovarian syndrome markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.77% during 2024-2034.
The polycystic ovarian syndrome market has been comprehensively analyzed in IMARC's new report titled "Polycystic Ovarian Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycystic ovarian syndrome (PCOS) refers to a common hormonal disorder that affects women, mainly during their reproductive years. It is characterized by a combination of irregular menstrual cycles, excess androgen levels (male hormones), and the formation of small cysts on the ovaries. The indications of the ailment can vary widely and may include irregular periods, heavy bleeding, excessive hair growth, acne, weight gain, etc. Due to hormonal imbalances, individuals suffering from this illness might also experience difficulties with fertility and an increased risk of developing conditions, such as type 2 diabetes, cardiovascular disease, depression, etc. The diagnosis of PCOS involves a comprehensive approach that considers both physical symptoms and hormone levels. The healthcare provider will recommend the Rotterdam criteria, which require the presence of at least two out of three features: irregular menstrual cycles, excess androgen activity, and polycystic ovaries observed via ultrasound. Accurate diagnosis is crucial for managing symptoms and preventing potential long-term health complications in patients.
The escalating incidences of hormonal imbalances and metabolic disturbances linked to insulin resistance, which can affect the reproductive and endocrine systems, are primarily driving the polycystic ovarian syndrome market. In addition to this, the inflating utilization of efficacious pharmaceutical interventions, including oral contraceptives, anti-androgen medications, and insulin-sensitizing agents, aimed at managing symptoms and mitigating further complications, is creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications and dietary adjustments, since they contribute to weight management, hormone regulation, and overall well-being, is also bolstering the market growth. Apart from this, the increasing application of assisted reproductive technologies and fertility treatments to address fertility challenges in individuals suffering from the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine approaches, which involve tailoring treatments based on patient's genetic and metabolic profiles to optimize outcomes, is also augmenting the market growth. Furthermore, the rising demand for innovative telemedicine platforms and digital health solutions for PCOS management on account of their several benefits, like facilitating remote monitoring, providing personalized guidance, and allowing for easy access to healthcare professionals, is expected to drive the polycystic ovarian syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the polycystic ovarian syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycystic ovarian syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycystic ovarian syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polycystic ovarian syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polycystic ovarian syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polycystic ovarian syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polycystic ovarian syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polycystic ovarian syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polycystic ovarian syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with polycystic ovarian syndrome across the seven major markets?
What is the size of the polycystic ovarian syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polycystic ovarian syndrome?
What will be the growth rate of patients across the seven major markets?
Polycystic Ovarian Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polycystic ovarian syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycystic ovarian syndrome market?
What are the key regulatory events related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by status related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by phase related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by route of administration related to the polycystic ovarian syndrome market?
The polycystic ovarian syndrome market has been comprehensively analyzed in IMARC's new report titled "Polycystic Ovarian Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycystic ovarian syndrome (PCOS) refers to a common hormonal disorder that affects women, mainly during their reproductive years. It is characterized by a combination of irregular menstrual cycles, excess androgen levels (male hormones), and the formation of small cysts on the ovaries. The indications of the ailment can vary widely and may include irregular periods, heavy bleeding, excessive hair growth, acne, weight gain, etc. Due to hormonal imbalances, individuals suffering from this illness might also experience difficulties with fertility and an increased risk of developing conditions, such as type 2 diabetes, cardiovascular disease, depression, etc. The diagnosis of PCOS involves a comprehensive approach that considers both physical symptoms and hormone levels. The healthcare provider will recommend the Rotterdam criteria, which require the presence of at least two out of three features: irregular menstrual cycles, excess androgen activity, and polycystic ovaries observed via ultrasound. Accurate diagnosis is crucial for managing symptoms and preventing potential long-term health complications in patients.
The escalating incidences of hormonal imbalances and metabolic disturbances linked to insulin resistance, which can affect the reproductive and endocrine systems, are primarily driving the polycystic ovarian syndrome market. In addition to this, the inflating utilization of efficacious pharmaceutical interventions, including oral contraceptives, anti-androgen medications, and insulin-sensitizing agents, aimed at managing symptoms and mitigating further complications, is creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications and dietary adjustments, since they contribute to weight management, hormone regulation, and overall well-being, is also bolstering the market growth. Apart from this, the increasing application of assisted reproductive technologies and fertility treatments to address fertility challenges in individuals suffering from the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine approaches, which involve tailoring treatments based on patient's genetic and metabolic profiles to optimize outcomes, is also augmenting the market growth. Furthermore, the rising demand for innovative telemedicine platforms and digital health solutions for PCOS management on account of their several benefits, like facilitating remote monitoring, providing personalized guidance, and allowing for easy access to healthcare professionals, is expected to drive the polycystic ovarian syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the polycystic ovarian syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycystic ovarian syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycystic ovarian syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polycystic ovarian syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polycystic ovarian syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polycystic ovarian syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polycystic ovarian syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polycystic ovarian syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polycystic ovarian syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of polycystic ovarian syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with polycystic ovarian syndrome across the seven major markets?
What is the size of the polycystic ovarian syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polycystic ovarian syndrome?
What will be the growth rate of patients across the seven major markets?
Polycystic Ovarian Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polycystic ovarian syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycystic ovarian syndrome market?
What are the key regulatory events related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by status related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by phase related to the polycystic ovarian syndrome market?
What is the structure of clinical trial landscape by route of administration related to the polycystic ovarian syndrome market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYCYSTIC OVARIAN SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYCYSTIC OVARIAN SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYCYSTIC OVARIAN SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POLYCYSTIC OVARIAN SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYCYSTIC OVARIAN SYNDROME - UNMET NEEDS
10 POLYCYSTIC OVARIAN SYNDROME - KEY ENDPOINTS OF TREATMENT
11 POLYCYSTIC OVARIAN SYNDROME - MARKETED PRODUCTS
11.1 List of Polycystic Ovarian Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 POLYCYSTIC OVARIAN SYNDROME - PIPELINE DRUGS
12.1 List of Polycystic Ovarian Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Elagolix - Abbvie/Neurocrine Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tildacerfont - Spruce Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYCYSTIC OVARIAN SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYCYSTIC OVARIAN SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYCYSTIC OVARIAN SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polycystic Ovarian Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polycystic Ovarian Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polycystic Ovarian Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polycystic Ovarian Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polycystic Ovarian Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polycystic Ovarian Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polycystic Ovarian Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polycystic Ovarian Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
16 POLYCYSTIC OVARIAN SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYCYSTIC OVARIAN SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYCYSTIC OVARIAN SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYCYSTIC OVARIAN SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYCYSTIC OVARIAN SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYCYSTIC OVARIAN SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POLYCYSTIC OVARIAN SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYCYSTIC OVARIAN SYNDROME - UNMET NEEDS
10 POLYCYSTIC OVARIAN SYNDROME - KEY ENDPOINTS OF TREATMENT
11 POLYCYSTIC OVARIAN SYNDROME - MARKETED PRODUCTS
11.1 List of Polycystic Ovarian Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 POLYCYSTIC OVARIAN SYNDROME - PIPELINE DRUGS
12.1 List of Polycystic Ovarian Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Elagolix - Abbvie/Neurocrine Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tildacerfont - Spruce Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYCYSTIC OVARIAN SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYCYSTIC OVARIAN SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYCYSTIC OVARIAN SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polycystic Ovarian Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polycystic Ovarian Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polycystic Ovarian Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polycystic Ovarian Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polycystic Ovarian Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polycystic Ovarian Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polycystic Ovarian Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polycystic Ovarian Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polycystic Ovarian Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polycystic Ovarian Syndrome - Access and Reimbursement Overview
16 POLYCYSTIC OVARIAN SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYCYSTIC OVARIAN SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYCYSTIC OVARIAN SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
